Track record · closed signal

Boston Scientific Corporation (BSX) — closed signal from July 11, 2025

Partial Published before the outcome was known, scored automatically when the window closed on October 9, 2025 — -6.3% at the close.

Predicted vs. what happened

BSX price · publication thesis → realized outcomesplit-adjusted

$102.00 – $105.00Entry zone — fair-value band

$103.86Published — price the day we called it

$120.48Target — the price the thesis aimed for

$109.50Peak — highest point inside the window, not a realized return

$97.28Window close — end-of-window price, context only

What happened

Partial

Reached 34% of the predicted growth at its peak, without hitting the target.

At window close

-6.3%

realized, from the publication price to the last close inside the window

Peak gain

+5.4%

peak, from the publication price — not a realized return

S&P 500, same window

+7.9%

SPY over the identical days, dividend-adjusted

Window close

$97.28

last close inside the window, ended October 9, 2025

Peak price

$109.50

peak on September 9, 2025 — not a realized return

Days to target

—

The thesis — published July 11, 2025

Predicted growth

+16%

over the measurement window

Target price

$120.48

the price the thesis aimed for

Entry zone

$102.00 – $105.00

the fair-value band we waited for

Price at publication

$103.86

published July 11, 2025

Confidence

72%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Recent changes in which industries investors favor pushed BSX lower than seems reasonable, even though the company keeps winning approvals for smart, AI-guided medical devices. A new Medicare proposal to pay for its kidney-nerve treatment hints at a much bigger pool of patients, and market surveys show optimism is very high. Observers think that if the share price closes above $106 it could advance toward $118 within about three months, while any slide is expected to find support near $98.

Primary drivers

Over 700 device approvals, many using AI, point to steady and growing sales.
Trading signals suggest the recent slide may be ending and a rebound could start.
Investor surveys show very strong interest after the recent market pullback.
The stock trades about 10 percent cheaper than rivals, giving room to catch up.

How it played out

BSX: target was not reached

Lyra published BSX at $103.86 on 2025-07-11, with expected growth of 16% over a short-term window. The thesis pointed to device approvals, artificial intelligence-guided medical devices, a Medicare proposal for kidney-nerve treatment, strong investor interest after a pullback, trading signals for a rebound, and a valuation about 10 percent cheaper than rivals.

Inside the window, BSX rose but did not reach the $120.48 target. It peaked at $109.50 on 2025-09-09, a 5.4% gain, then ended the window at $97.28 on 2025-10-09. The thesis partially played out early, but the target was missed.

What happened during the window

On 2025-07-23, Boston Scientific reported second-quarter results, and Investors.com said sales rose 23% year over year to $5.06 billion. On the same date, MarketWatch reported that BSX closed at $107.76 after rising 4.46%.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All BSX signals